For patients with ischemic stroke, tenecteplase seems to be a reasonable alternative to alteplase in terms of effectiveness and safety outcomes.

Disappointment over a cardiology board, an FDA approval, meeting news, and advice for practice—it’s all here this month.

Roche said it has removed its thrombolytic drug tenecteplase from phase 3 for for acute ischaemic stroke, along with several earlier-stage projects. The fibrin-specific plasminogen activator ...

Fibrin-specific plasminogen activator TNKase (tenecteplase) is the first stroke medicine approved by the FDA in nearly 30 years, joining Roche/Genentech's Activase (alteplase), which is the only ...

Swiss pharma giant Roche RHHBY faced a setback in its efforts to develop a higher dose of multiple sclerosis drug Ocrevus ...

Medscape News UK, March 28, 2025 Tenecteplase Matches Alteplase for Ischemic Stroke Care Tenecteplase provides comparable safety and effectiveness outcomes for acute ischemic stroke as alteplase ...

In a post hoc pooled analysis of the EXTEND-IA (Endovascular Therapy for Ischemic Stroke With Perfusion-Imaging Selection) and EXTEND-IA TNK (Tenecteplase Versus Alteplase Before Thrombectomy for ...

For patients with mainly mild posterior circulation ischemic stroke who do not receive thrombectomy, alteplase administered ...